融合基因转录本检测的微小残留病对KMT2A重排婴儿急性淋巴细胞白血病的预后价值
该研究在76例≤1岁KMT2A重排急性淋巴细胞白血病婴儿中,评估了融合基因转录本检测的微小残留病(FGT-MRD)的预后价值。诱导结束时或后续时间点FGT-MRD阳性均与不良结局相关;因此,单时间点FGT-MRD检测可区分传统化疗可治愈与需其他治疗的婴儿。
要点
- 诱导结束或后续时间点FGT-MRD阳性与KMT2A重排婴儿ALL不良结局相关。
- 单时间点FGT-MRD检测有助于区分传统化疗可治愈与需其他治疗方案的婴儿。
核心结论
- 在KMT2A重排婴儿ALL中,FGT-MRD阳性(诱导结束或后续时间点)与不良结局相关。
- 单时间点FGT-MRD检测可区分传统化疗可治愈与仅受益于其他治疗方法的婴儿。
研究设计与样本
- 研究纳入76例年龄≤1岁的KMT2A重排急性淋巴细胞白血病婴儿。
- 采用融合基因转录本检测微小残留病(FGT-MRD),评估其在诱导结束及后续时间点的预后价值。
主要发现
- 诱导结束或后续时间点FGT-MRD阳性与不良结局相关。
- 多变量分析证实了FGT-MRD阳性的预后价值。
临床怎么用
- 在KMT2A重排婴儿ALL中,可通过单时间点FGT-MRD检测(如首次巩固或首次高危block后)识别传统化疗可治愈与需其他治疗方案的婴儿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognostic value of minimal residual disease (MRD) measured by fusion-gene transcript (FGT) detection was investigated in 76 infants (aged ≤1 year) with acute lymphoblastic leukaemia (ALL) with lysine methyltransferase 2A (KMT2A) rearrangements. Either at the end of induction or at later time-points, FGT-MRD-positivity was associated with poor outcome. FGT-MRD-positivity after first consolidation or first high-risk block detected 46·5% of infants with extremely poor outcome [disease-free survival (SE) 0·06 (0·06), cumulative incidence of relapse (SE) 0·91 (0·05)], which was also confirmed in multivariable analysis. Thus, FGT-MRD measurement at a single time-point clearly identifies infants with ALL who are curable with conventional chemotherapy and those who would benefit only from other treatment approaches.
引用
- Tsaur G, Popov A, Riger T, et al. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol. Br J Haematol. 2021. PMID: 33583020. doi:10.1111/bjh.17304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。